Reneo Pharmaceuticals is a clinical-stage pharmaceutical company founded in 2014 and based in the United States. The company is dedicated to developing and commercializing therapies for patients with rare genetic mitochondrial diseases. They focus on addressing the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo's lead product candidate, mavodelpar (REN001), functions as a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Clinical studies have shown that mavodelpar can increase the transcription of genes involved in mitochondrial function and fatty acid oxidation, potentially stimulating the production of new mitochondria. Reneo Pharmaceuticals received a significant $55.00M Post-IPO Equity investment on 03 May 2023. The investors involved in this last investment round were not specified. For more detailed information, visit reneopharma.com. Please note that Reneo's communications on LinkedIn are targeted at U.S. audiences exclusively. You can find their Digital Media Guidelines here: https://reneopharma.com/digital-media-community-guidelines/.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $55.00M | - | 03 May 2023 | |
| Post-IPO Secondary | $20.00M | - | 01 May 2022 | |
| Series B | $95.00M | 10 |
|
09 Dec 2020 |
| Series A | $50.00M | - | 20 May 2019 |
No recent news or press coverage available for Reneo Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
